mardi 17 avril 2018

Onco Actu du 17 avril 2018

1.4 Biologie - Technos

DNA Barcodes Make for Better Single-Cell Analysis [NIH Director's Blog]

2.11 Etiologie - Alimentation

Coffee industry worried U.S. ruling on cancer warning may widen [Reuters]

4. Dépistage, diagnostic et pronostic

U.S. public may lack understanding of cancer screening [Reuters]

4.2 Dép., diag. & prono. - Génome

New additions to the cancer precision medicine toolkit [Genome Medicine]

5.1 Traitements - Pré-clinique

A breast cancer study in mice gets big headlines, setting up potential for patient ‘disaster,’ experts say [HealthNewsReview]

5.12.2 Immunothérapies - CAR-T

Engineered immune cells clear deadly pediatric brain tumor in mice [Stanford Medicine]

5.2.2 Pharma - Fusions & Acquisitions

Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer [FiercePharma]

5.9 AACR

AACR Annual Meeting 2018: Opening Plenary Session on Liquid Biopsy, Immunotherapy, and More [Cancer Research Catalyst]

Advancing Patient Care Through Focused Innovation [NCI]

These are the top priorities for the nation’s top cancer doctor [Washington Post]

5.9.3 AACR - mélanome

Merck's Keytruda builds its melanoma case against Opdivo with postsurgery trial win [FiercePharma]

5.9.4 AACR - poumon

CheckMate -227 Met its Co-primary Endpoint of Progression-free Survival [AACR]

Neoadjuvant Nivolumab was Safe, Yielded Pathologic Responses in Patients With Resectable Lung Cancer [AACR]

KEYNOTE-189 Met its Dual Primary Endpoints of Overall Survival and Progression-free Survival [AACR]

Merck extends its lead in immuno-oncology with ‘practice-changing’ lung cancer data [STAT]

Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study [Merck]

In a monster showing, Merck's Keytruda combo slashes lung cancer death risk by half [FiercePharma]

BMS' Opdivo-Yervoy combo posts big win in first-line lung cancer—but big enough to challenge Merck? [FiercePharma]

For More Lung Cancer Patients, the Promise of No Chemo Looms Larger [Xconomy]

Merck Immunotherapy Drug Shines In Lung Cancer Study [NPR]

Merck Tightens Its Grip on the Lung-Cancer Market [Bloomberg]

Survival data boosts Merck's Keytruda lead in lung cancer [Reuters]

#AACR18: Roche spotlights promising subgroup responses for lung cancer combo with Tecentriq [EndPoints]

Immunotherapy-first cancer treatment a 'game-changer', say scientists [The Telegraph]

Adding Merck's Keytruda To Chemo Halves Death Risk For Lung Cancer Patients [Forbes]

New Drug Combinations Improve Survival in Lung Cancer [Wall Street Journal]

For advanced lung cancer, immune therapy plus chemo prolongs survival [Washington Post]

Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB) [BMS]

Lung Cancer Patients Live Longer With Immune Therapy [NY Times]

5.9.5 AACR - CAR-T

An Off-the-shelf, Dual-targeted CAR T-cell Product Showed Promising Results in Preclinical Studies [AACR]

5.9.7 AACR - divers

Antibody Combo Expands Response to Checkpoint Inhibitor in Mice [The Scientist]

6.6 Publications

Tighten Up Your Numbers! [In the Pipeline]

6.7.1 IA/bioinformatique

Lords report endorses PHG Foundation recommendation on AI [PHG Foundation]